HUTCHMED has encountered significant challenges on two fronts, with a recently launched "star drug" being withdrawn from the market due to safety concerns, while its established core products have experienced declining sales. On March 9, HUTCHMED announced that, following a notification from its partner Ipsen, it has initiated the withdrawal and recall of the drug Tazverik (tazemetostat) in mainland China, Hong Kong, and Macau, and has halted all related clinical trials. Tazverik was launched in China less than a year ago, in March of last year. The withdrawal was triggered by concerns that the drug may increase the risk of secondary hematological malignancies. The National Healthcare Security Administration responded swiftly, removing the drug from provincial procurement platforms and excluding it from the commercial health insurance innovative drug directory. This makes Tazverik the first drug to be removed from the national commercial health insurance innovative drug directory due to safety issues. According to the announcement, Tazverik generated $2.5 million in sales last year. For HUTCHMED, however, the withdrawal represents more than just a financial blow; it also disrupts the specialized sales team that had been assembled for the product and interrupts the subsequent pipeline strategy. Meanwhile, HUTCHMED's annual report shows that domestic sales of its core products—fruquintinib, surufatinib, and savolitinib—declined by 13% to 45% last year. The company is now under pressure from both its new and established business lines.
The primary reason for the withdrawal stems from the ongoing SYMPHONY-1 Ib/III study conducted by Ipsen, which was evaluating Tazverik in combination with lenalidomide and rituximab (the R2 regimen) compared to the R2 regimen alone for the treatment of follicular lymphoma. According to Ipsen's communication, an independent data monitoring committee, after reviewing the latest data from the SYMPHONY-1 study, recommended that the potential risks of the treatment regimen—based on adverse events related to secondary hematological malignancies—may outweigh the potential benefits for patients. Based on these findings, Ipsen decided to immediately withdraw Tazverik from the market for both its follicular lymphoma and epithelioid sarcoma indications. The company also initiated procedures to discontinue Tazverik treatment for all patients in the SYMPHONY-1 study.
Tazverik is a first-in-class EZH2 methyltransferase inhibitor. Its monotherapy received accelerated approval from the U.S. FDA in 2020 for the treatment of specific patient groups with relapsed or refractory follicular lymphoma and epithelioid sarcoma. In China, Tazverik was conditionally approved by the National Medical Products Administration as an imported drug in March of last year for the treatment of adult patients with EZH2 mutation-positive relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. It was included in the commercial health insurance innovative drug directory last December. In response to the withdrawal, the National Healthcare Security Administration has removed Tazverik tablets from all provincial drug procurement platforms effective March 9 and, following the company's application, excluded it from the Commercial Health Insurance Innovative Drug Directory (2025). This event marks a significant shift in China's drug regulation and medical insurance access, moving from a focus on initial approval to dynamic lifecycle management. It underscores a zero-tolerance policy towards drug safety risks and challenges the assumption that inclusion in the insurance directory guarantees long-term stability. Future医保准入 for conditionally approved drugs is expected to become more cautious.
Tazverik was originally developed by Epizyme, a company under Ipsen. In 2021, HUTCHMED entered into a strategic collaboration with Epizyme, securing the rights to research, develop, manufacture, and commercialize Tazverik in mainland China, Hong Kong, Macau, and Taiwan. Under the agreement, Epizyme received an upfront payment of $25 million, with potential development and regulatory milestone payments of up to $110 million, sales milestone payments of up to $175 million, and additional royalties. Since Tazverik only received approval in China last year and the first prescription was written in July, its commercialization period was short, resulting in sales of just $2.5 million for the year. HUTCHMED had regarded Tazverik as an important introduced product. In its annual report disclosed on March 5, the company stated that it had "established a professional team responsible for the sales of Tazverik and other investigational hematology drugs, with the expectation of achieving commercialization through its own team in the coming years." The current withdrawal and product recall in mainland China, Hong Kong, and Macau, along with the halt of ongoing clinical trials for Tazverik, means that while the short-term financial impact on HUTCHMED may be limited, the strategic losses are significant in the medium to long term. The specialized hematology sales team assembled for the product may now be underutilized, and the upfront authorization fees, research and development, and commercialization costs invested by the company are likely to become sunk costs. This incident also highlights a core risk of the license-in model: Chinese regional rights are highly dependent on the global decisions of the originator, with local companies having limited control over clinical development and withdrawal decisions. Over-reliance on early overseas data without independent verification capabilities can easily lead to a situation where a global withdrawal forces a passive follow-up in the domestic market.
Beyond the Tazverik withdrawal, HUTCHMED's annual report indicates that several of its core products performed poorly last year. The company's total revenue was $549 million, a decrease of 12.96% year-on-year. Excluding the base effect from a $20 million milestone payment received from Takeda in 2024, the combined revenue from its oncology/immunology business was $286 million, down 21.44% year-on-year, which was a major factor dragging down overall revenue. HUTCHMED has four drugs approved in mainland China: fruquintinib, surufatinib, savolitinib, and Tazverik. Fruquintinib is approved or marketed in 39 countries and regions globally, including China, the U.S., the European Union, and Japan. According to the financial report, domestic sales of fruquintinib, surufatinib, and savolitinib all declined last year. Fruquintinib's domestic sales were $100 million, down 13% year-on-year; surufatinib sales were $27 million, down 45%; and savolitinib sales were $28.9 million, down 36%. HUTCHMED attributed the sales performance of surufatinib and savolitinib to market competition, including new competition from drugs newly included in the National Reimbursement Drug List and intense competition in the MET exon 14 skipping non-small cell lung cancer treatment领域. The only areas of growth for HUTCHMED last year were the overseas sales of fruquintinib and the sales of Tazverik. In its announcement, HUTCHMED emphasized that "this withdrawal is not expected to impact the company's financial guidance." The company's full-year guidance for consolidated oncology/immunology revenue this year, as provided in its financial report, is $330 million to $450 million. According to pharmaceutical industry analysis, for HUTCHMED to achieve its financial guidance for this year, three key variables will be crucial. First is the continued sales expansion of fruquintinib overseas; overseas sales of the drug reached nearly $290 million in 2024, a nearly twenty-fold increase year-on-year, making it the core growth engine. The pace of overseas market expansion is therefore critical. Second is cost control and R&D efficiency; while HUTCHMED's R&D expenses have decreased in recent years, achieving the revenue guidance of $330 million to $450 million will require controlling costs while enabling the R&D pipeline to create value as soon as possible. Third is the stabilization of the domestic market for core products; although domestic sales of fruquintinib, surufatinib, and savolitinib have declined, new indications are being pursued. If these can contribute incremental revenue quickly, they may help offset some of the decline.
Comments